Zanubrutinib Outperforms Acalabrutinib in Adjusted Head-to-Head Analysis - Prabadin Corp

https://prabadinews.com/

Email

weborders@prabadincorp.com

Call us

+1 (786)-332-3938

Zanubrutinib Outperforms Acalabrutinib in Adjusted Head-to-Head Analysis

Health

July 16, 2025

By AdminPrabadin - 2 months ago

0

An adjusted analysis of the ALPINE and ASCEND trials revealed a statistically significant progression-free survival advantage for Zanubrutinib.

administrator